These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 31264346

  • 21. Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patient-level pooled analysis of EDITION 1, 2 and 3.
    Bonadonna RC, Yale JF, Brulle-Wohlhueter C, Boëlle-Le Corfec E, Choudhary P, Bailey TS.
    Diabetes Obes Metab; 2019 Mar; 21(3):715-719. PubMed ID: 30414260
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension).
    Terauchi Y, Koyama M, Cheng X, Sumi M, Riddle MC, Bolli GB, Hirose T, EDITION JP 2 study group.
    Diabetes Metab; 2017 Oct; 43(5):446-452. PubMed ID: 28433560
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Evaluating the clinical effectiveness and safety of insulin glargine 300 U/mL in individuals with type 2 diabetes uncontrolled on basal insulin: A real-world evidence study from Saudi Arabia (EVOLUTION).
    Al Malki F, El Damanhoury B, Othman A, Alghamdi Z, AlQahtani M, Madgy A, Chouikrat Z.
    Diabetes Obes Metab; 2023 Oct; 25(10):2869-2877. PubMed ID: 37485767
    [Abstract] [Full Text] [Related]

  • 26. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
    Bolli GB, Riddle MC, Bergenstal RM, Ziemen M, Sestakauskas K, Goyeau H, Home PD, on behalf of the EDITION 3 study investigators.
    Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
    [Abstract] [Full Text] [Related]

  • 27. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension.
    Riddle MC, Yki-Järvinen H, Bolli GB, Ziemen M, Muehlen-Bartmer I, Cissokho S, Home PD.
    Diabetes Obes Metab; 2015 Sep; 17(9):835-42. PubMed ID: 25846721
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta-analysis of 6-month phase 3 clinical trials.
    Danne T, Matsuhisa M, Sussebach C, Goyeau H, Lauand F, Niemoeller E, Bolli GB.
    Diabetes Obes Metab; 2020 Oct; 22(10):1880-1885. PubMed ID: 32515543
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Switching the basal insulin to insulin glargine 300 U/ml in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safety.
    Seufert J, Wiesli P, Fritsche A, Anderten H, Pegelow K, Pscherer S, Pfohl M.
    Diabetes Obes Metab; 2022 Jan; 24(1):72-81. PubMed ID: 34514696
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring.
    Pettus J, Gill J, Paranjape S, Stewart J, Malla S, Edelman S, Bergenstal RM, Bode B.
    Diabetes Obes Metab; 2019 Aug; 21(8):1906-1913. PubMed ID: 30993855
    [Abstract] [Full Text] [Related]

  • 35. A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study.
    Meneghini LF, Sullivan SD, Oster G, Busch R, Cali AMG, Dauchy A, Gill J, Bailey TS.
    Diabetes Obes Metab; 2020 Nov; 22(11):2004-2012. PubMed ID: 32729217
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Hypoglycaemia and treatment patterns among insulin-treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real-world setting.
    Zhou FL, Nicholls C, Xie L, Wang Y, Vaidya N, Meneghini LF.
    Endocrinol Diabetes Metab; 2019 Jul; 2(3):e00073. PubMed ID: 31294087
    [Abstract] [Full Text] [Related]

  • 38. Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes.
    Ritzel R, Roussel R, Giaccari A, Vora J, Brulle-Wohlhueter C, Yki-Järvinen H.
    Diabetes Obes Metab; 2018 Mar; 20(3):541-548. PubMed ID: 28862801
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures.
    Lingvay I, Chao J, Dalal MR, Meneghini LF.
    Diabetes Technol Ther; 2017 May; 19(5):315-322. PubMed ID: 28467113
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.